Infectious disease
Origin, a 3D printing specialist for medical devices, just completed clinical trials and validation of its 3D-printed nasopharyngeal swabs for use in COVID-19 test kits. It is scaling up production and accepting orders to manufacture millions of the swabs.
It’s likely that more companies and universities will add additional assets as time goes on.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
Moderna’s mRNA Zika vaccine data is becoming helpful in the development of the COVID-19 vaccine. The company is using the elements to faster the process of producing the vaccine.
The two companies are eying the second half of this year to begin clinical trials on their combined project and, if the vaccine meets expectations, the companies said it could be available for use in the second half of 2021.
Although the COVID-19 death toll has not yet reached the numbers of H3N2, it still continues to climb.
The U.S. Food and Drug Administration granted emergency use authorization to Rutgers’ RUCDR Infinite Biologics for its test that uses saliva.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 13, 2020.
In its daily blog about the precautions the company is taking to ensure continued service to the world, Amazon said it will build its own testing facilities for employees.
The study of the 53 patients in the U.S., Europe and Canada who required respiratory support showed that about two-thirds benefited from the drug.
PRESS RELEASES